摘要
目的观察利培酮治疗躯体化障碍患者的增效作用。方法127例躯体化障碍患者随机分为研究组(利培酮+西酞普兰)64例、对照组(西酞普兰)63例,治疗6个月。于治疗前,治疗后1、2、4、6个月末测评汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、不良反应量表(TESS)。疗效评价以HAMD减分率为标准,不良反应以TESS评分为标准。结果2组HAMD、HAMA评分组间比较均从治疗1个月末开始差异有统计学意义(P<0.05),2组疗效比较差异有统计学意义(P<0.05);各时期TESS评分比较差异无统计学意义(P>0.05)。结论利培酮合并抗抑郁剂治疗躯体化障碍具有增效作用。
Objective To observe the additional benefits by risperidone in treatment of somatization disorders. Methods One hundred and twenty-seven patients with somatization disorders were randomly divided into study group （risperidone＋ eitalopram, n=64） and control group （eitalopram, n=63） on a 6-month therapy. The patients were assessed with HAMD, HAMA and TESS before treatment and at 1, 2, 4 and 6 months after treatment. The efficacy was evaluated based on reduetion rate of HAMD, and the adverse effects based on TESS. Results Significant differenees in HAMD and HAMA were observed between two groups starting fi＇om the end of first month after treatment （P〈0.05）, but not in TESS for all times （P〉0.05）. Conclusion Risperidone added on antidepressants may provide additional benefits in treatment of somatization disorders.
出处
《中国药物与临床》
CAS
2010年第4期389-390,共2页
Chinese Remedies & Clinics
基金
浙江省绍兴市科技局基金(2009A33005)
关键词
躯体型障碍
生物医学研究
利培酮
Somatoform disorders
Biomedical research
Risperidone
